Conclusion
Results strongly suggest that isothiocyanate-based H2S-releasing drugs, such as compound 25, can trigger a ''pharmacological pre-conditioning" and could represent a suitable pharmacological option in antiischemic therapy.
Methods
A library of forty-five isothiocyanates, selected for their different chemical properties, has been evaluated for its hydrogen sulfide (H2S) releasing capacity. The obtained
Results
The results herein obtained strongly indicate 3-pyridyl-isothiocyanate (25) as a suitable pharmacological option in anti-ischemic therapy. The cardioprotective effects of compound 25 were tested in vivo and found to exhibit a positive effect.